The newest project of JGL, a pharmaceutical company from Rijeka, serves as proof that investing in knowledge and technological processes can lead to added value whose quality and innovation gain recognition on the global market. The unique formula of JGL’s Meralys brand, which sprouted from research and development laboratories of this successful Croatian company, has recently been capitalised on, being licensed by Actavis, a multinational specialty pharmaceutical company present in over 60 global markets.
Licensing-out, a cooperation process commonly found in business-to-business (B2B) pharmaceutical transactions, has been realised with Actavis for ten EU markets – Sweden, Norway, Finland, Denmark, Iceland, Bulgaria, Ireland, Romania, Slovakia and Switzerland – and has been capitalised on using know-how with a licence for a development dossier.
The product has no direct global competition and has been launched by JGL in 2011, after five years of research and development. The product will now be sold by Actavis under the company’s own brands, while JGL will act as the exclusive manufacturer. The uniqueness of this preparation definitely lies in the fact that for the very first time a decongestant has been dissolved in a seawater solution which nourishes the mucosa with salts and microelements.
It cannot be denied that with achievements such as this, the increasingly successful Croatian company continues to perform professionally, position itself on the global pharmaceutical map and prove that knowledge and experience of its own experts can indeed successfully compete on the global market.